Concurrently, integration of chemokine receptors such as CXCR2 or CCR4 enhances CAR-γδT responsiveness to tumor-derived chemokines, improving tumor infiltration and local efficacy (18, 192, 193). The gene discussed is CXCR2; the disease is neoplasm.